Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-059416
Filing Date
2026-05-12
Accepted
2026-05-12 16:18:59
Documents
104
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ibio-20260331x10q.htm   iXBRL 10-Q 2027470
2 EX-31.1 ibio-20260331xex31d1.htm EX-31.1 15609
3 EX-31.2 ibio-20260331xex31d2.htm EX-31.2 18769
4 EX-32.1 ibio-20260331xex32d1.htm EX-32.1 10994
5 EX-32.2 ibio-20260331xex32d2.htm EX-32.2 5687
6 GRAPHIC ibio-20260331x10q001.jpg GRAPHIC 68684
7 GRAPHIC ibio-20260331x10q002.jpg GRAPHIC 67793
  Complete submission text file 0001104659-26-059416.txt   10385482

Data Files

Seq Description Document Type Size
8 EX-101.SCH ibio-20260331.xsd EX-101.SCH 83543
9 EX-101.CAL ibio-20260331_cal.xml EX-101.CAL 50991
10 EX-101.DEF ibio-20260331_def.xml EX-101.DEF 388894
11 EX-101.LAB ibio-20260331_lab.xml EX-101.LAB 591406
12 EX-101.PRE ibio-20260331_pre.xml EX-101.PRE 571012
108 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20260331x10q_htm.xml XML 1650336
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

EIN.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-35023 | Film No.: 26968882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)